BioInvent's BI — 1808 shows tumor regression in Phase 1 cancer trial
BioInvent announced published first-in-human Phase 1 results for BI-1808 in Clinical Cancer Research, showing preliminary antitumor activity in advanced solid tumors. Treatment was well tolerated, with no dose-limiting toxicities, deaths or discontinuations due to drug-related adverse events. A gastrointestinal stromal